Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47,898,935
-
Total 13F shares
-
55,851,715
-
Share change
-
+4,675,932
-
Total reported value
-
$4,621,294,419
-
Put/Call ratio
-
13%
-
Price per share
-
$82.73
-
Number of holders
-
315
-
Value change
-
+$385,980,667
-
Number of buys
-
166
-
Number of sells
-
137
Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q2 2024
As of 30 Jun 2024,
HAEMONETICS CORP - Common Stock (HAE) was held by
315 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,851,715 shares.
The largest 10 holders included
Capital Research Global Investors, BlackRock Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, NEUBERGER BERMAN GROUP LLC, STATE STREET CORP, T. Rowe Price Investment Management, Inc., FRANKLIN RESOURCES INC, ROYCE & ASSOCIATES LP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
315
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.